Supplementary Information

Stabilization of dimeric PYR/PYL/RCAR family members relieves abscisic acid-induced inhibition of seed germination

Zhi-Zheng Wang^{1, †}, Min-Jie Cao^{2, †}, Jun-Jie Yan^{3, †}, Jin Dong^{1, †}, Mo-Xian Chen⁴, Jing-Fang Yang¹, Jian-Hong Li⁴, Rui-Ning Ying¹, Yang-Yang Gao⁴, Li Li³, Ya-Nan Leng⁶, Yuan Tian⁷, Kamalani Achala H. Hewage¹, Rong-Jie Pei¹, Zhi-You Huang¹, Ping Yin³, Jian-Kang Zhu^{2,*}, Ge-Fei Hao^{1,4,*}, and Guang-Fu Yang^{1,*}

¹ State Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensor Technology and Health, Central China Normal University, Wuhan, 430079, China

² Shanghai Center for Plant Stress Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai, 200032, China

⁴ State Key Laboratory of Crop Genetic Improvement and National Centre of Plant Gene Research, Huazhong Agricultural University, Wuhan, 430070, China

⁵ State Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals, Guizhou University, Guiyang, 550025, China

⁶ State Key Laboratory of Tree Genetics and Breeding, the Southern Modern Forestry Collaborative Innovation Center, Key Laboratory of State Forestry and Grassland Administration on Subtropical Forest Biodiversity Conservation, College of Life Sciences, Nanjing Forestry University, Nanjing, 210037, China

⁷ State Key Laboratory of Crop Biology, College of Life Science, Shandong Agricultural University, Taian, Shandong, 271018, China

[†] These authors contributed equally to this work.

*To whom correspondence should be addressed. *gefei_hao@foxmail.com*, *jkzhu@psc.ac.cn*, *gfyang@mail.ccnu.edu.cn*

Supplementary Table 1. The binding free energy (kcal/mol) of compounds generated using fragment growing approach.

012 H . K.								
No.	Substituents	ΔE_{ele}	ΔE_{vdw}	ΔE_{MM}	ΔG_{sol}	ΔE_{bind}	$-T \triangle S$	ΔG_{cal}
1	O ₂ N Br	-20.65	-49.85	-70.50	38.21	-32.29	20.06	-12.23
2	- Ar	-20.66	-46.00	-66.66	36.07	-30.59	18.58	-12.01
3	° , ° , r	-23.58	-53.19	-76.58	44.66	-32.92	21.56	-11.36
4		-23.86	-47.37	-71.23	38.32	-32.81	21.54	-11.27
5		-19.37	-43.62	-62.99	33.68	-29.31	18.31	-11.00
6	Arr N	-18.32	-50.99	-69.31	39.67	-29.64	18.65	-10.99
7		-16.89	-45.08	-61.97	33.72	-28.25	17.35	-10.90
8	N-O	-17.90	-47.08	-64.98	34.79	-30.19	18.35	-10.84
9	O2N	-22.40	-47.51	-69.91	38.61	-31.30	20.75	-10.55
10	NH ₂	-18.86	-40.48	-59.34	33.53	-25.71	16.33	-9.38

Br

	PYL1-DBSA (PDB ID: 9J6I)		
Data collection			
Space group	P65		
Cell dimensions			
<i>a, b, c</i> (Å)	126.99, 126.99, 60.195		
α, β, γ (°)	90, 90, 120		
Resolution (Å)	41.67-2.29 (2.37-2.29)		
Rmerge	0.027 (0.435)		
Ι/σ (Ι)	13.35 (1.82)		
Completeness (%)	100.00 (98)		
Redundancy	2.0 (2.0)		
Refinement			
Resolution (Å)	2.29		
No. reflections	50745 (4891)		
Rwork/Rfree (%)	20.67/25.23		
No. atoms			
Protein	2722		
Ligand/ion	24		
Water	38		
B-factors			
Protein	71.2		
Ligand/ion	76.8		
Water	61.2		
R.m.s. deviations			
Bond lengths (Å)	0.009		
Bond angles (°)	1.035		

Supplementary Table 2. Data collection, phasing, and refinement statistics of PYL1-DBSA (PDB code: 9J6I).

Values in parentheses are for the highest resolution shell. $R_{merge} = \sum_h \sum_i |I_{h,i} - I_h| / \sum_h \sum_i I_{h,i}$, where I_h is the mean intensity of the *i* observations of symmetry related reflections of *h*. $R = \sum |F_{obs} - F_{calc}| / \sum F_{obs}$, where F_{calc} is the calculated protein structure factor from the atomic model (R_{free} was calculated with 5% of the reflections selected).

	ABA-PYR1	apo-PYL1	DBSA-PYL1
$\Delta E_{\rm ele}$	-96.42	-113.69	-138.42
$\Delta E_{ m vdw}$	-55.10	-104.97	-129.37
$\Delta E_{\rm GB}$	102.24	160.33	187.85
$\Delta E_{\rm SA}$	-12.91	-12.86	-11.25
ΔG_{cal}	-62.19	-71.19	-91.18

Supplementary Table 3. The binding free energy between two monomers of PYL dimers under the existence of ABA or BDSA (kcal/mol).

System	Acceptor	Donor	Frac ^a	AvgDist ^b	AvgAng ^c
PYR1-ABA	B_Lys_63@NZ	A_Asp_155@OD1	0.6264	2.9	138.9
	B_Lys_63@NZ	A_Asp_155@OD2	0.5880	3.0	156.2
	A_Ser_85@OG	B_Asp_155@O	0.5636	2.9	172
apo-PYL1	B_Lys_69@NZ	A_Asp_164@OD1	0.8288	3.3	130.9
	A_Lys_69@NZ	B_Asp_164@OD1	0.7664	3.0	167.2
	B_Pro_94@ND2	B_Arg_122@ND2	0.6636	2.9	159.7
	B_Pro_94@ND2	B_Arg_122@ND2	0.6616	3.2	132.7
DBSA-PYL1	DBSA@O-	A_SER_112@OG	0.9044	2.9	140.4
	A_Ser_112@O	B_Asn_160@ND2	0.7380	2.9	140.5
	A_Asn_88@ND2	A_Lys_69@NZ	0.6672	2.8	144.1
	A_Lys_69@NZ	B_Asp_164@OD1	0.9244	2.9	155.0
	A_Lys_69@NZ	B_Asp_164@OD2	0.9632	2.9	135.1
	B_Lys_69@NZ	A_Asp_164@OD1	0.8912	2.8	161.5
	B_Lys_69@NZ	A_Asp_164@OD2	0.8536	2.9	138.2
	A_Asn_160@ND2	B_Ala_95@ND2	0.5632	3.0	153.3
	B_Pro_94@ND2	B_Arg_122@ND1	0.6896	2.7	140.9
	B_Pro_94@ND2	B_Arg_122@ND2	0.7132	2.8	144.8

Supplementary Table 4. The hydrogen bond analysis of PYR1-ABA, *apo*-PYL1 and PYL1-DBSA during MD simulations.

^a Hydrogen bond occupancy. ^b Average hydrogen bond distance. ^c Average hydrogen bond angle.



Supplementary Fig. 1. The detailed optimization of pyrabactin for fragment growing. Pyrabactin could act as ABA receptor agonist (PYR1 and PYL1) or antagonist (PYL2). Binding mode of pyrabactin as antagonist to gate open PYL2 (PDB code 3NR4) was analyzed, and steric clash was occurred to gate open PYL1 (PDB code 3KAY). To avoid steric clash and find a proper conformation for dimer stabilizer design, the pyridine group should be removed, and molecular docking was performed on the rest of molecules. It could be noticed that conformation towards dimer interface was easy to cause steric clash with gate open and latch open PYL1. And molecule was finally optimized into 4bromobenzenesulfonamide group, which was binding tightly to gate-open and latchopen PYL1 by forming hydrogen bonds with Arg143.



Supplementary Fig. 2. The ITC results of DBSA to PYL5, PYL6 and PYL10.



Supplementary Fig. 3. (a) ITC experiment results of dropping ABA into a cell containing PYR1 and DBSA. (b) ITC experiment results of dropping DBSA into a cell containing PYR1 and ABA.



Supplementary Fig. 4. The HAB1 activity of treatment with different concentration of DBSA but without PYLs. (n = 3 biologically replicates). The data are presented as the mean \pm SD, the line within the box marks the median and the whiskers represent the minimum and maximum values.



Supplementary Fig. 5. The representative response unique DEGs and pathways enriched for both ABA and DBSA based on functional enrichment analysis (p < 0.01).



Supplementary Fig. 6. The final $2Fo-F_C$ map (A) and an unbiased $Fo-F_C$ map (B) obtained after omitting the ligand from the X-ray crystal structure.



Supplementary Fig. 7. The comparison between predicted model and x-ray crystal structure of PYL1-DBSA complex (PDB code 9J6I). The crystal structure shared a similar structure with our predicted model. The prediction model was shown in pink stick model, and X-ray crystal structure was shown in green stick model.



Supplementary Fig. 8. The RMSD plot during MD simulations of PYRR1-ABA, apo-PYL1 and PYL1-DBSA.



Supplementary Fig. 9. The function motion of ABA-PYR1, *apo*-PYL1 and DBSA-PYL1.



Supplementary Fig. 10. The motion trends of apo-PYL1.



Supplementary Fig. 11. The dominant conformations were determined using FEL analysis.



Supplementary Fig. 12. The hydrogen networks mediated by apo-PYL1 in the dimer interfaces.



Supplementary Fig. 13. Seed germination experiment of different concentration of ABA and DBSA on WT *Arabidopsis thaliana* seeds.

Supplementary Note 1. The synthesis of NBSA and DBSA



Reagents and conditions: a). Pyridine, CH₂Cl₂, 0 ℃- reflux; b). nitric acid, CH₃COOH, r.t.-80 ℃; c). nitric acid, CH₃COOH, 90 ℃.

Synthesis of 4-bromo-N-(4-bromophenyl)benzenesulfonamide (3):

A solution of 4-bromobenzenesulfonyl chloride(2.2 mmol, 561 mg) in $CH_2Cl_2(4 mL)$ was added dropwise to a solution of 4-bromoaniline(2 mmol, 344 mg) and pyridine(6 mmol, 474 mg) in ice-cold $CH_2Cl_2(4 mL)$. Then, the resulting mixture was heated at reflux for 2 h, cooled, acidified with hydrochloric acid, and extracted with $CH_2Cl_2(3\times15 mL)$. The CH_2Cl_2 was removed in vacuo to give the crude mixture which was purified by column chromatography on silica gel to the desired product as a white solid (**3**).

Synthesis of 4-bromo-N-(4-bromo-2-nitrophenyl)benzenesulfonamide (4, NBSA):

Intermediate **3**(1 mmol, 391 mg) was dissolved in acetic acid (6 mL) in a 25 mL single neck flask, and nitric acid (0.4 mL) was added by dropwise to the solution at room temperature. The reaction mixture was allowed to 80°C and stirred for a further 0.5 h before the residue was cooled with ice water (10 mL), and extracted with ethyl acetate (3×10 mL). Then the ethyl acetate solution was concentrated to give the crude mixture which was purified by column chromatography on silica gel to the desired product as a yellow solid (**4**). Yield 72 %; m.p. 127.3-128.1 °C; ¹H NMR (600 MHz, CDCl₃) δ 9.79 (s, 1H), 8.28 (s, 1H), 7.76 (d, *J* = 9.0 Hz, 1H), 7.71 (d, *J* = 9.0 Hz, 3H), 7.64 (d, *J* = 8.4 Hz, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 138.79, 137.26, 137.22, 132.79, 132.43, 129.20, 128.80, 128.60, 122.25, 116.53. HRMS (ESI): m/z [M+Na]⁺ calcd for, C₁₂H₈Br₂N₂NaO₄S : 456.8469 ; found: 456.8464.



4-bromo-N-(4-bromo-2,6-dinitrophenyl)benzenesulfonamide (5, DBSA):

Additional nitric acid (0.4 mL) was added to the reaction after the mononitration reaction is completed. The resulting mixture was then heated at 90°C for 1.5 h, cooled, added ice water (10 mL), and extracted with ethyl acetate (3×10 mL). The ethyl acetate solution was concentrated, and the crude mixture was purified by column chromatography on silica gel to the desired product as a yellow solid (**5**). Yield 55 %; m.p. 198.1-198.9 °C; ¹H NMR (600 MHz, CDCl₃) δ 8.33 (s, 1H), 8.30 (s, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H). ¹³C NMR (150 MHz, DMSO-*d*₆) δ 148.72, 138.89, 132.54, 131.87, 128.49, 127.36, 121.60, 121.00. HRMS (ESI): m/z [M+Na]⁺ calcd for, C₁₂H₇Br₂N₃NaO₆S : 501.8320 ; found: 501.8332.



190 180 170 160 150 140 130 120 110 100 90 80 70 60 f1 (ppm)